| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 10/25/2001 | CA2399940A1 Enhancement of antibody-mediated immune responses |
| 10/25/2001 | CA2396762A1 Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21 |
| 10/25/2001 | CA2376882A1 Novel recombinant antibody, amino acid sequences of its complementarity determining regions and genes encoding the same |
| 10/24/2001 | EP1147212A1 T helper cell epitopes |
| 10/24/2001 | EP1147201A2 Metalloproteinase-disintegrin family members: svph dnas and polypeptides |
| 10/24/2001 | EP1147194A1 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies |
| 10/24/2001 | EP1147190A1 Her-2/neu fusion proteins |
| 10/24/2001 | EP1147136A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 10/24/2001 | EP1147131A1 Alleviation of the allergenic potential of airborne and contact allergens by thioredoxin |
| 10/24/2001 | EP1147117A1 Immunological adjuvant compounds |
| 10/24/2001 | EP1146907A2 Use of cationic lipids to generate anti-tumor immunity |
| 10/24/2001 | EP1146906A1 Mucosal delivery system |
| 10/24/2001 | EP1146904A1 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv |
| 10/24/2001 | EP1146902A1 Treatment of autommune diseases by an agonistic cd40-binding protein |
| 10/24/2001 | EP1146901A1 Potentiation of anti-cd38-immunotoxin cytotoxicity |
| 10/24/2001 | EP1146900A2 Dna vaccines against hantavirus infections |
| 10/24/2001 | EP1146899A1 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders |
| 10/24/2001 | EP1146898A1 Vaccine-mediated treatment of neurological disorders |
| 10/24/2001 | EP1146893A1 Neurite derived growth factors for use in the treatment of muscular dystrophy |
| 10/24/2001 | EP1146892A2 Baff, inhibitors thereof and their use in the modulation of the b-cell response |
| 10/24/2001 | EP1146889A2 Identification of specific differentially expressed mycobacterial antigens |
| 10/24/2001 | EP1146881A2 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 10/24/2001 | EP1146861A1 Hydrogel particle formulations |
| 10/24/2001 | EP1146858A1 Non-invasive vaccination through the skin |
| 10/24/2001 | EP1146845A2 Compressed lecithin preparations |
| 10/24/2001 | EP1146789A1 Treating cancers associated with overexpression of her-2/neu |
| 10/24/2001 | EP0910405B1 Vaccine containing caprine arthritis-encephalitis virus and use for immunoprotection against hiv-1 infection |
| 10/24/2001 | EP0828511B1 Haemophilus influenzae type b vaccine composition containing polyribosylribitol phosphate and method for making the same |
| 10/24/2001 | EP0809698B1 NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF TUMOR GENE Int6 |
| 10/24/2001 | EP0731709B1 Neutrophil inhibitors from nematodes |
| 10/24/2001 | EP0710117B1 Phosphazene polyelectrolytes as immunoadjuvants |
| 10/24/2001 | EP0593754B1 Peptides of human papilloma virus for use in human t cell response inducing compositions |
| 10/24/2001 | CN1319140A Recombinant CELO virus and CELO virus DNA |
| 10/24/2001 | CN1319105A Methods for produsction of antibodies to specific regions of cyclosporine and cyclosporine metabolites |
| 10/24/2001 | CN1319019A i(ex vivo) treatment of allogeneic and xanogeneic T-cells with gp39 antagonists |
| 10/24/2001 | CN1318646A Coded salmonella typhi specific and antigenic outer membrane protein DNA sequence |
| 10/24/2001 | CN1318565A Humanized hapotitis A virus neutralizing genetically engineered total antibody |
| 10/24/2001 | CN1318561A Human testicular mitosis dynein gene encoded protein |
| 10/24/2001 | CN1318560A Human testicular specific protein-1 gene encoded protein |
| 10/24/2001 | CN1318555A Human testicular development relative protein gene encoded protein |
| 10/24/2001 | CN1318554A Human testicular development specific protein-11 gene encoded protein |
| 10/24/2001 | CN1073447C Freeze-dried attenuated living vaccine of hepatitis A |
| 10/23/2001 | USRE37416 Method for manufacturing a modular semiconductor power device |
| 10/23/2001 | US6307038 Nucleotide sequences coding fusion protein for use in treatment of oxidative stress |
| 10/23/2001 | US6307028 Chromatographic method for high yield purification and viral inactivation of antibodies |
| 10/23/2001 | US6307022 Def |
| 10/23/2001 | US6306900 Enteric coated pharmaceutical compositions |
| 10/23/2001 | US6306653 Peptide for use in diagnosis, prevention and treatment of mammary gland cancer |
| 10/23/2001 | US6306651 Bone marrow hematopoietic stem cell; for use in prevention of graft versus host disease |
| 10/23/2001 | US6306640 Melanoma antigenic peptides |
| 10/23/2001 | US6306637 Production of virus and purification of viral envelope proteins for vaccine use |
| 10/23/2001 | US6306623 Leptospiral major outer membrane protein LipL32 |
| 10/23/2001 | US6306612 Methods of facilitating vascular growth |
| 10/23/2001 | US6306581 Diagnostic assay method and kit for the detection of HHV-8 infection |
| 10/23/2001 | US6306580 Preparation of human papillomavirus E1 having helicase activity and method therefor |
| 10/23/2001 | US6306579 Immunoassay by incubating sample with at least one peptide from ns3 region having at least one covalently modified cysteine or replaced cysteine, then determining binding of antibody to peptide |
| 10/23/2001 | US6306405 Use of microparticles combined with submicron oil-in-water emulsions |
| 10/23/2001 | US6306404 As adjuvant for vaccines |
| 10/23/2001 | US6306402 Compounds and methods for the diagnosis and treatment of EHRLICHIA infection |
| 10/23/2001 | US6306401 Genetically-engineered sindbis virus with modified E2 Glycoprotein and altered host-range phenotype |
| 10/23/2001 | US6306400 For immunization of chickens |
| 10/23/2001 | US6306397 Variants of human papilloma virus antigens |
| 10/23/2001 | US6306396 Compounds and methods for the diagnosis and treatment of B. microti infection |
| 10/23/2001 | US6306394 Nucleic acids, proteins, and methods of use of granulocytic ehrlichia |
| 10/23/2001 | US6306393 Administering to subject having a b-cell related malignancy a therapeutic composition comprising a pharmaceutically acceptable carrier and a combination of at least one naked anti-cd19 antibody and an anfi-cd20 antibody |
| 10/23/2001 | US6306388 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 10/23/2001 | US6306387 Antigen delivery system |
| 10/23/2001 | US6306385 Method of protecting against chronic infections |
| 10/23/2001 | US6306365 Method of identifying molecules that home to a selected organ in vivo |
| 10/23/2001 | CA1341308C Vaccines against avian herpes viruses |
| 10/23/2001 | CA1341307C Nucleotide sequences of avian herpes viruses |
| 10/18/2001 | WO2001077358A2 Herpes viruses for immune modulation |
| 10/18/2001 | WO2001077342A1 Multivalent antibodies and uses therefor |
| 10/18/2001 | WO2001077339A1 Human pyruvate dehydrogenese phosphatase |
| 10/18/2001 | WO2001077335A2 Listeria monocytogenes genome, polypeptides and uses |
| 10/18/2001 | WO2001077322A1 Cryptic-like secreted protein |
| 10/18/2001 | WO2001077301A1 Tumor cells transformation process |
| 10/18/2001 | WO2001077299A2 A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS |
| 10/18/2001 | WO2001077181A2 Anti-rhesus d monoclonal antibodies |
| 10/18/2001 | WO2001077179A1 Proteins with a high immunoreactivity and a method for the production thereof |
| 10/18/2001 | WO2001077168A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 10/18/2001 | WO2001077160A1 A modified h-ns peptide of salmonella typhimurium, capable of modulating the oligomerization of h-ns |
| 10/18/2001 | WO2001077158A1 Hepatitis b core antigen fusion proteins |
| 10/18/2001 | WO2001077156A2 Neutralizing immunogenic hev polypeptides |
| 10/18/2001 | WO2001077149A2 Regulation of human cyslt2-like gpcr protein |
| 10/18/2001 | WO2001077146A2 Compounds and methods for modulating endothelial cell adhesion |
| 10/18/2001 | WO2001077137A1 Albumin fusion proteins |
| 10/18/2001 | WO2001076643A1 Macroaggregated protein conjugates as oral genetic immunization delivery agents |
| 10/18/2001 | WO2001076641A1 Targeted death of cancer cells |
| 10/18/2001 | WO2001076628A1 Chlamydial glycolipid vaccines |
| 10/18/2001 | WO2001076627A1 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
| 10/18/2001 | WO2001076626A2 Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants |
| 10/18/2001 | WO2001076625A1 Iscom polypeptide delivery system |
| 10/18/2001 | WO2001076624A1 Inactivated japanese b encephalitis vaccine and process for producing the same |
| 10/18/2001 | WO2001076623A1 Iscom polypeptide delivery system for helicobacter pylori antigens |
| 10/18/2001 | WO2001076622A2 Immunogenic peptides derived from prostate-specific antigen (psa) and uses thereof |
| 10/18/2001 | WO2001076617A2 Oral tolerance induction by collagen to prevent allograft rejection |
| 10/18/2001 | WO2001076558A1 Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
| 10/18/2001 | WO2001076531A2 Bile acid containing prodrugs with enhanced bioavailability |
| 10/18/2001 | WO2001076381A1 Protein stabilised emulsions |